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Abstract
Purpose: 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT), a cell proliferation positron emission
tomography (PET) tracer, has been shown in numerous tumors to be more specific than 2-
deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) but less sensitive. We studied the capacity of a
nontoxic concentration of 5-fluoro-2′-deoxyuridine (FdUrd), a thymidine synthesis inhibitor, to
increase uptake of [18F]FLT in tumor xenografts.
Methods: The duration of the FdUrd effect in vivo on tumor cell cycling and thymidine analogue
uptake was studied by varying FdUrd pretreatment timing and holding constant the timing of
subsequent flow cytometry and 5-[125I]iodo-2′-deoxyuridine biodistribution measurements. In
[18F]FLT studies, FdUrd pretreatment was generally performed 1 h before radiotracer injection.
[18F]FLT biodistributions were measured 1 to 3 h after radiotracer injection of mice grafted with
five different human tumors and pretreated or not with FdUrd and compared with [18F]FDG tumor
uptake. Using microPET, the dynamic distribution of [18F]FLT was followed for 1.5 h in FdUrd
pretreated mice. High-field T2-weighted magnetic resonance imaging (MRI) and histology were
used comparatively in assessing tumor viability and proliferation.
Results: FdUrd induced an immediate increase in tumor uptake of 5-[125I]iodo-2′-deoxyuridine,
that vanished after 6 h, as also confirmed by flow cytometry. Biodistribution measurements
showed that FdUrd pretreatment increased [18F]FLT uptake in all tumors by factors of 3.2 to 7.8
compared with controls, while [18F]FDG tumor uptake was about fourfold and sixfold lower in
breast cancers and lymphoma. Dynamic PET in FdUrd pretreated mice showed that [18F]FLT
uptake in all tumors increased steadily up to 1.5 h. MRI showed a well-vascularized
homogenous lymphoma with high [18F]FLT uptake, while in breast cancer, a central necrosis
shown by MRI was inactive in PET, consistent with the histomorphological analysis.
Correspondence to: David Viertl; e-mail: David.Viertl@chuv.ch
Conclusion: We showed a reliable and significant uptake increase of [18F]FLT in different tumor
xenografts after low-dose FdUrd pretreatment. These results show promise for a clinical application of
FdUrd aimed at increasing the sensitivity of [18F]FLT PET.
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Introduction
Positron emission tomography (PET) is routinely used forcancer diagnosis, staging, and therapy monitoring. In
many cancers, tumor cell proliferation is an important
prognostic factor and is a key factor to monitoring efficacy
of anticancer therapy. Therefore, radiopharmaceuticals
directly related to cell proliferation, such as 3′-deoxy-3′-
[18F]fluorothymidine ([18F]FLT), which targets the DNA
synthesis, are highly relevant, and are promising for PET
applications.
Several reagents have been proposed for PET imaging or
γ-scintigraphy of tumor cell proliferation, including [123I] and
[124I]iodo-2′-deoxyuridine (IdUrd,), [76Br]bromodeoyxuridine,
[11C]thymidine, and derivatives of deoxy-[18F]fluoro-
arabinofuranosyl such as [18F]FAU, [18F]FMAU, [18F]FBAU,
and [18F]FIAU. While a number of these radiotracers were
tested in clinical studies, [18F]FLT has emerged as the most
promising PET tracer in recent studies [1]. Currently, several
prospective clinical trials involving [18F]FLT are ongoing in
patients with breast, lung, head, and neck cancer and glioblas-
toma (NCT00566293, NCT01015131, NCT00534274,
NCT00847509, NCT00721799, NCT00624728).
[18F]FLT has several advantages compared with some of
the other radiopharmaceuticals. While [11C]thymidine or
radio-IdUrd derivatives are rapidly degraded in vivo, [18F]
FLT is biologically stable and crosses the cell membrane by
specific nucleoside transporters. Once in the cytoplasm,
[18F]FLT is trapped through phosphorylation by thymidine
kinase 1. Since thymidine kinase 1 expression increases in
cells undergoing DNA synthesis (S phase), cytoplasmic
uptake of [18F]FLT reflects the proliferative activity of cells
[2]. Prior studies have established that [18F]FLT uptake
correlates with Ki-67 immunostaining proliferation assay, in
breast cancer [3], lung cancer [4], and leukemia [5], and with
S phase fraction in lung tumors as measured by flow
cytometry [6]. Tumor imaging with [18F]FLT PET has been
shown to be generally specific in cancer diagnosis [7].
However, nonspecific incorporation can be observed in
proliferating macrophages in inflammatory lesions [8]. It
also appears to predict outcome after chemotherapy [9],
radiotherapy [10] as well as progression and overall survival
of patients with brain tumors [11]. Moreover, in breast
cancer [12] and in high-grade non-Hodgkin’s lymphoma
[13], early change in [18F]FLT uptake, immediately after
initiation of chemotherapy predicts tumor response to treat-
ment. Thus, [18F]FLT might be an important adjunct in the
therapeutic management of cancer patients.
Currently, 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) is
the most frequently used PET imaging agent for character-
ization of mass lesions and assessment of response to
treatment in a variety of tumors [14]. [18F]FDG, as a
glucose analogue, is internalized in cells with enhanced
glucose requirement. [18F]FDG incorporation has been
found to be correlated with cellular proliferation [15] and,
hence, has been considered an indicator of tumor aggressive-
ness [16]. However, it is a matter of debate whether glucose
consumption is a good indicator of tumor aggressiveness.
[18F]FDG uptake is not specific for tumor cells and can be
found in nonneoplastic lesions, notably in inflammation and
repair. Furthermore, high physiological cerebral glucose
uptake limits its usefulness in brain tumor imaging.
Different studies have shown higher specificity of [18F]
FLT in comparison with [18F]FDG [17], but lower sensi-
tivity due to limited [18F]FLT tumor uptake. This is a major
drawback for its widespread clinical application. In fact,
only cells undergoing division are susceptible to incorpo-
ration of [18F]FLT. Moreover, injected [18F]FLT has to
compete with endogenous thymidine, which further limits its
uptake in proliferating cells.
In this study, we addressed part of these limitations by
modifying cellular uptake of extracellular thymidine, by
interfering with the endogenous DNA synthesis pathway
using 5-fluoro-2′-deoxyuridine (FdUrd, floxuridine). We
hypothesized that pretreatment with FdUrd might be able
to increase tumor uptake of [18F]FLT. Here, FdUrd was used
in mice at a nontoxic bolus injection of 2.5 mg/kg, while
intravenous (i.v.) bolus treatment in humans is performed
with 30 mg/kg [18]. We studied the effect of FdUrd in mice
bearing different human tumor xenografts by biodistribution
studies and animal PET.
Materials and Methods
Radiopharmaceuticals and Reagents
[18F]FLT was produced at the Center for Radiopharmaceutical
Science of the Swiss Federal Institute of Technology at Zürich
(Switzerland) according the procedure reported by Kim et al. [19].
The specific activity was 281±204 GBq/µmol, and the purity was
≥97% for all preparations.
5-[125I]iodo-2′-deoxyuridine ([125I]IdUrd) of high radiochemical
purity was prepared in house using a modified method, originally
described by Foulon et al. [20]. In all experiments, [125I]IdUrd
represented ≥97% of overall I-125 activity.
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Clinical grade [18F]FDG was provided by Advanced Acceler-
ator Applications (AAA; Saint Genis Pouilly, France).
FdUrd and 5′-deoxythymidine (dThd) were obtained from
Sigma-Aldrich Chemie GmbH (Steinheim, Germany). IdUrd
(Sigma-Aldrich Chemie GmbH) was dissolved in distilled water
using NaOH alkalinization at minimally required concentration.
Cell Lines and Culture
Two Burkitt lymphomas (Ramos and BL60.2), two human breast
adenocarcinomas (MDA-MB231, SKBR127), and two human
colon adenocarcinomas (WiDr, LS174T9) were used. All cell lines
except BL60.2 (kindly provided by Dr. Stephan Mathas at
Delbrück-Center for Molecular Medicine, Berlin, Germany) were
obtained fromAmerican Type Culture Collection. Cells were cultured
at 37°C and 5% CO2 in RPMI 1640 containing glutamax I
(Invitrogen, Grand Island, NY) supplemented with 10% heat-
inactivated fetal bovine serum (Chemie Brunschwig AG, Basel,
Switzerland), penicillin (50 units/mL) and streptomycin (0.05mg/mL;
from Life Technologies Inc., Grand Island, NY).
Since mycoplasma contamination is a source of increased nucleo-
side turnover that therefore modulates FdUrd efficacy and cellular
uptake of thymidine, cells were cultured for 6 months after thawing
and tested negative for mycoplasma contaminations (Mycoplasma
Detection Kit; F. Hoffmann-La Roche Ltd, Basel, Switzerland).
Mice and Tumor Models
All experiments were performed according to the principles of
laboratory animal care and Swiss legislation. The experiments were
specifically approved by the official committee on surveillance of
animal experiments. Female homozygous athymic Foxn1nu/nu nude
and CB17 SCID mice were obtained from Harlan Laboratories
(Boxmeer, Netherlands). Animals were kept under specific patho-
gen-free conditions, in autoclaved filter-topped cages and bedding in a
separate room.Mice had access ad libitum to sterilized food and water.
Suspensions of 5×106 cells in 0.07 to 0.1 mL cell culture media
were inoculated subcutaneously at inguinal (for biodistribution
studies) or thoracic level (for PET studies) in mice of 6 to 8 weeks
of age. Experiments were performed after adequate growth of
tumors 12 days to 4 weeks after grafting. For experiments including
magnetic resonance imaging (MRI), tumors were grafted subcuta-
neously onto the skull of mice.
Flow Cytometry and [125I]IdUrd Incorporation
Measurements
For these experiments, pretreatment timing was varied between
FdUrd injection and IdUrd or [125I]IdUrd injection. The timing of
analysis post-IdUrd injection was 1 h after unlabeled IdUrd and 5 h
after [125I]IdUrd.
Tumor xenografts were analyzed by two-parameter flow
cytometry. Mice bearing BL60.2 and Ramos tumors received 3,
10, or 30 mg/kg FdUrd i.v. After varying pretreatment intervals (1,
3, and 6 h), the animals were injected intraperitoneally with 1 mg
IdUrd and euthanized by CO2 inhalation 1 h thereafter. Control
groups were not pretreated with FdUrd and received only IdUrd.
Tumors were excised, dissociated with a tissue grinder, and washed.
Aliquots of 106 cells were labeled with anti-BrdU fluorescein
isothiocyanate (FITC) and propidium iodide following the method in
the Becton Dickinson source book section 3.80.1 (Becton Dickinson
Immunocytometry Systems, San Jose, CA). Flow cytometry (FACS-
can; Becton Dickinson, Franklin Lakes, NJ) was performed with a
laser excitation at 488 nm for PI and FITC fluorescence.
Two days before [125I]IdUrd biodistribution measurements,
mice were given 0.2 g/L KI in drinking water to block I-125
uptake in thyroid and 1 g/L KClO4, to inhibit iodine secretion in
stomach. Mice were pretreated with 5 mg/kg FdUrd injected i.v. in
2 fractions separated by 30 min. After (1, 3, and 10 h) FdUrd
pretreatment, 10 kBq [125I]IdUrd was injected into tumor. Animals
were euthanized 5 h after [125I]IdUrd injection, and biodistribution
was measured in dissected tumors and tissues. Mean ± 1 SD of
results were expressed in percentage of injected dose per gram
tissue (% ID/g).
[18F]FLT and [18F]FDG Biodistribution Studies
The effect of mild FdUrd conditioning on [18F]FLT tumor uptake
was assessed in mice bearing Ramos, MDA-MB231, SKBR3,
LS174T, and WiDr xenografts. The protocol used for biodistribu-
tion studies was adapted from Dupertuis et al. [21].
FdUrd pretreated mice received a single i.v. injection of 2.5 mg/kg
FdUrd, and 1 h after FdUrd injection, unless stated differently, 1 MBq
[18F]FLT was injected in the lateral tail vein. In one experiment, a
10-min delay after FdUrd was compared with a 1-h delay. Control
mice received [18F]FLT only. Mice were euthanized by CO2
inhalation, 1, 2, or 3 h after [18F]FLT administration. The tumors, all
major normal organs (liver, kidney, lung, spleen, heart, stomach, and
large and small intestine) and samples of tissues (blood, quadriceps
muscle, skin, and femoral bone) and the rest of the carcasses were
dissected and weighted, and radioactivity was measured in a γ-counter
(1480 Wizard 3; PerkinElmer, Schwerzenbach, Switzerland).
Specificity of [18F]FLT tissue uptake under FdUrd enhancement
was assessed by competition experiments, using an excess of dThd.
Both injections of FdUrd and [18F]FLT were enriched with 20 mg/kg
dThd each.
Biodistributions of [18F]FDG were measured in groups of four
mice bearing both MDA-MB231 and SKBR3 tumors and five mice
with double grafts of Ramos tumors. Mice were fasted for a
minimum of 6 h before i.v. injection of 1 MBq [18F]FDG. During
[18F]FDG experiments, mice were maintained under anesthesia
using 1% isoflurane delivered in oxygen at 1 L/min and warmed to
31°C. Two hours after [18F]FDG administration, mice were
euthanized by CO2 inhalation and dissected, and organs were
weighed and counted as previously described.
Small-Animal PET
Imaging was performed using an avalanche photodiode microPET
scanner (LabPET4; Gamma Medic-Ideas, Sherbrooke, Quebec,
Canada). During the entire scanning period, mice were maintained
under 1% isoflurane anesthesia in oxygen delivered at 1 L/min
using a face mask and under monitoring of temperature and
breathing rate. For dynamic PET, all animals were pretreated with
2.5 mg/kg FdUrd. List-mode acquisitions of 90 min were initiated
1 min after injection of 24.8±6.0 MBq [18F]FLT, via the lateral tail
vein. An energy window of 250–650 keV and a coincidence-timing
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window of 22.2 ns were used. Images were reconstructed by the
MLEM iterative method. Images were corrected for nonuniformity
of scanner response, dead time count losses, and physical decay to
the time of injection.
Images were analyzed with the PMOD 3.0 software (PMOD
Technologies, Zurich, Switzerland). For dynamic studies, regions
of interest were drawn manually by optical reading of well-
delineated normal tissues like heart on early frames and tumors
on late frames. These regions of interest were then projected on all
dynamic images. Time activity curves were calculated for different
areas (tumor, heart, bone, and abdominal activity) and were
expressed in kBq/mL.
Magnetic Resonance Imaging
Scans were performed on a 9.4 Tesla Varian (Varian Medical
Systems, Palo Alto, CA) 21-cm horizontal-bore scanner with a 12-cm
200-mT/m gradient insert (Magnex Scientific, Oxford, UK) [22].
Respiration was monitored during the measurement, and body
temperature was maintained at 37°C. MRI was performed for head
implanted tumors, using tight immobilization of the animal head with
bilateral ear pins and maxillary fixation. Multislice fast-spin-echo T2-
weighted images (using a repetition time of 4 s and an echo time of
50 ms) were obtained in the coronal and transverse planes using a field
of view of 20×20mm, a slice thickness of 0.7mm, and amatrix size of
256×256 image voxels.
Tumor Histology and Immunohistochemistry
Tumors were fixed with 4% neutral buffered formalin and
embedded in paraffin. For Ki-67 immunostaining, 4-µm-thick
sections were cut from paraffin blocks, deparaffinized in xylene,
and rehydrated in graded ethanol. Sections were incubated over-
night at 4°C with monoclonal mouse antihuman Ki-67 antibody
(Dako Schweiz, Baar, Switzerland). For determination of tumor
proliferative rate, 1,000 cells per slide were counted at 40×
magnification using a standard diagnostic microscope and KI-67-
positive cells expressed in percentage of total tumor cells. Standard
hematoxylin–eosin (HE) staining was used for evaluation of tumor
cell viability and general histological examination. The mitotic index
of each tumor was determined by counting the number of mitotic
figures on 10 different 40× magnification field of views. Data were
expressed as mean ± 1 SD per 10 high power field (HPF).
Statistical Analysis
To evaluate the increase in the mean tumor uptake values during
the late period (20 last min) of dynamic PET scanning, two
different time frames were compared with each other using the
Student’s t test. The activity measured over five frames of 1 min
each, one starting at 66 min, and the other at 86 min was compared,
and P values G 0.05 were considered statistically significant. The
Mann–Whitney nonparametric test was used to assess whether
tumor uptake of [18F]FLT in FdUrd-pretreated animals was differ-
ent from control groups, PG0.05 being considered significant and
PG0.01 highly significant. Both statistical tests were two sided.
Tests were performed using the statistical analysis software SPSS
(version 15.0; SPSS, Inc., Chicago, IL).
Results
Timing Dependence of FdUrd Efficacy on Tumor
Cells In Vivo
Cell cycle modification induced by FdUrd in vivo was
studied by flow cytometry experiments. In BL60.2 and
Ramos lymphoma tumors, cell cycle determination was only
possible in mice having been pretreated with FdUrd. Without
FdUrd pretreatment, IdUrd based S phase staining failed to
produce a measurable two-dimensional separation of cells. In
BL60.2 cells, the ratio of S phase cells was already high at 1 h
after administration of FdUrd (50.6%±7.3%) and was similar
at 3 h (50.4%±2.7%). Thereafter, the staining of S phase cells
was lost and no longer measurable at 6 h after FdUrd
pretreatment. Similarly, in mice bearing Ramos tumors, the
number of cells in S phase was very high (61.7%±0.2% of the
whole viable cell population) but limited in time, and at 6 h
post-FdUrd, the signal vanished (Fig. 1; Table 1). Variations
in the amount of FdUrd injected (3, 10, and 30 mg/kg) did not
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Fig. 1. Examples of flow cytometry histograms of cell distribution in the cell cycle stages (G0/G1, S, and G2/M). Results without
FdUrd pretreatment or at 1, 3, and 6 h post-30 mg/kg FdUrd i.v. injection are shown.
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provide differences in the percentage of cells in S phase nor in
the duration of measurable S phase staining (results not shown).
The effect of FdUrd over time was also assessed by
biodistribution measurements of [125I]IdUrd in mice bearing
Ramos tumors. Three pretreatment time points (1, 3, and
10 h) between FdUrd and intratumoral injection of [125I]
IdUrd were chosen. Mice were euthanized 5 h after [125I]
IdUrd injection, and the residual activity found in tumor and
normal tissues was counted. The baseline activity without
FdUrd pretreatment was 29.5%±8.5% ID/g in the tumors.With
1 h between FdUrd and [125I]IdUrd injections, tumor activity
was significantly increased to a peak of 256.2%±81.9% ID/g.
As the interval between FdUrd and [125I]IdUrd injections
increased, the intratumoral activity decreased to 99.6%±5.0%
and 56.3%±1.3% ID/g at 3 and 10 h, respectively.
[18F]FLT and [18F]FDG Biodistribution Studies
The effect of a single injection of 2.5 mg/kg FdUrd i.v. 1 h
before injection of [18F]FLT was tested in mice grafted with
different types of human tumors.
In four groups of mice bearing Ramos lymphoma
xenografts, biodistribution of [18F]FLT was measured at 1
and 3 h after injection of [18F]FLT. Tumor uptake of [18F]
FLT in control mice (without FdUrd pretreatment) was
moderate with 7.7%±1.3% and 9.4%±1.5% ID/g at 1 and
3 h, respectively. In FdUrd-pretreated mice, [18F]FLT tumor
uptake was significantly increased with 42.4%±5.8% and
41.3%±5.8% ID/g at 1 and 3 h, respectively (Fig. 2a;
Table 2). Due to washout from nonneoplatsic tissues, high
retention of [18F]FLT in tumors of pretreated mice led to
markedly improved tumor-to-normal-tissue ratios at 3 h after
[18F]FLT injection (Fig 2b). The absence of increased [18F]
FLT uptake in spleen and bone marrow after FdUrd
pretreatment in these mice might be explained by the fact
that they had been treated by whole-body irradiation
(2.5 Gy) before tumor transplantation in order to facilitate
engraftment of the lymphoma. The biodistribution experi-
ment was performed 11 days after irradiation when bone
marrow and spleen cells remained depressed. Biodistribution
of [18F]FDG in fasted and anesthetized mice showed that the
Ramos tumors incorporated 6.7%±1.2% ID/g 2 h after [18F]
FDG injection (Fig. 2c).
Based on the results in lymphoma xenografts and clinical
experience reporting a higher sensitivity by increasing the
delay between injection and acquisition in [18F]FDG PET in
breast cancer, biodistribution of [18F]FLT in mice grafted
with MDA-MB231 and SKBR3 human breast carcinomas
was measured 2 h after injection of [18F]FLT. FdUrd
enhanced the uptake of [18F]FLT in MDA-MB231 and
SKBR3, compared with nonpretreated mice, by a mean
factor of 4.7 and 3.2, respectively (Fig. 3a; Table 2). In
MDA-MB231 tumors, baseline incorporation of [18F]FLT
was 6.3%±1.6% ID/g rising, after FdUrd pretreatment, to
29.4%±5.8% ID/g. In SKBR3 tumors, uptake in untreated
mice was 5.3%±1.0% ID/g compared with 17.1%±4.7% ID/g
after FdUrd injection (Fig. 3a; Table 2).
The specificity of the [18F]FLT uptake in FdUrd pre-
treated mice was confirmed by competitive inhibition with
an excess of dThd. In these mice, tumor uptake decreased to
2.0%±0.5% and to 2.4%±0.6% ID/g in MDA-MB231 and
SKBR3 xenografts, respectively (Fig. 2a).
For comparison, [18F]FDG biodistribution was performed
2 h postinjection in fasted and anesthetized mice bearing
also MDA-MB231 and SKBR3 breast cancer xenografts.
The [18F]FDG tumor uptake was 6.6%±0.4% and 4.3%±
1.0% ID/g in MDA-MB231 and SKBR3 tumors, respec-
tively (Fig. 3b). We had obtained very similar [18F]FDG
biodistribution and tumor uptake results, except for muscle,
in a pilot study in nonanesthetized, but otherwise identically
treated mice (results not shown).
In a separate experiment aiming to further optimize the
accumulation of [18F]FLT within tumor cells, the timing of
injection was varied in groups of three mice, each bearing
two xenografts of the MDA-MB231 breast cancer cell line.
In mice without FdUrd pretreatment, the baseline tumor
incorporation of [18F]FLT, measured 2 h after radiotracer
injection, was rather low with 2.1%±0.2% ID/g. FdUrd
pretreatment of mice 10 or 60 min before [18F]FLT injection
and dissection at 2 h after radiotracer administration yielded
a dramatic increase in tumor uptake, with mean values of
16.6%±2.1% and 15.8%±2.5% ID/g, respectively (Table 3).
When mice, pretreated 1 h before injection of [18F]FLT,
were analyzed at 1 h after radiotracer injection, tumor uptake
of 15.8%±3.5% ID/g was very similar to the results of
dissection after 2 h, but as expected, the activity in normal
tissues was markedly higher at 1 h.
In order to reproduce these findings in another tumor
type, the effect of FdUrd was measured in mice bearing
LS174T and WiDr colon cancer xenografts. In control mice,
Table 1. Percentage of cells in the G0/G1, S, and G2/M phase of the cell cycle as observed by double-staining flow cytometry
Without FdUrd 1 h post-FdUrd 3 h post-FdUrd 6 h post-FdUrd
BL60.2 G1/G0 N.A
a 34%±3% 36%±3% 44%±2%b
S NAa 51%±7% 50%±3% 24%±7%b
G2/M NA
a 7%±1% 5%±1% 8%±1%b
Ramos G1/G0 NA
a 35%±1% 30%±1% 44%±2%b
S NAa 56%±1% 62%±1% 34%±1%b
G2/M NA
a 2%±1% 2%±1% 6%±1%b
aNonapplicable or bpartially relevant only in the case of two-parameter flow cytometry due to insufficient incorporation of exogenous IdUrd
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tumor uptake was 8.5%±4.1% and 5.7%±2.2% ID/g in
LS174T and WiDr, respectively. After FdUrd pretreatment,
mean tumor uptake in LS174T and WiDr xenografts
increased 4.3- and 5.8-fold, reaching 36.3%±14.5% and
32.9%±9.8% ID/g, respectively (Fig. 4; Table 2).
Dynamic [18F]FLT PET
All tested tumors (Ramos, MDA-MB231, SKBR3, LS174T,
and WiDr) continuously took up [18F]FLT over 90 min of
dynamic PET (Fig. 5). For all tumors, the [18F]FLT activity
was below intra-abdominal background activity immediately
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Fig. 3. a Biodistributions of [18F]FLT without or with FdUrd
pretreatment in mice bearing MDA-MB231 and SKBR3
tumors. Column break ( ): spleen = 79.3%±31.7% ID/g in
mice with FdUrd pretreatment. b Biodistributions of [18F]FDG.
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Fig. 2. a Biodistributions measured in mice bearing Ramos
xenografts and euthanized 1 and 3 h, respectively, after i.v.
injection of 1 MBq [18F]FLT. Column break ( ): spleen =
80.9%±38.6% ID/g. b Histogram of the tumor-to-normal-
tissue ratios in FdUrd-pretreated mice, in comparison with
mice analyzed 1 and 3 h after [18F]FLT injection. c Biodis-
tributions of [18F]FDG (y-scale same as in a to facilitate
comparison).
Table 2. Summary of the mean tumor uptake in control and FdUrd
pretreated mice
Cell lines Ta [18F]FLT tumor uptake (% ID/g) Mean fold
increase
in uptake
Nbb
Control With FdUrd
Ramos 1 h 7.7 ± 1.3 42.4±5.8** 5.5 4
3 h 9.4±1.5 41.3±5.7** 4.4 3
MDA-MB231 2 h 6.3±1.6 29.4±5.8* 4.7 5
SKBR3 2 h 5.3±1.0 17.1±4.7* 3.2 5
LS 174T 2 h 8.5±4.1 36.3±14.5* 4.3 3
WiDr 2 h 5.7±2.2 32.9±9.8* 5.8 3
aLength of time between [18F]FLT injection and biodistribution
measurement
bNumber of mice per group
Mann–Whitney test *significantly different (PG0.05) and **highly different
(P G 0.01)
Summary of the [18F]FLT tumor uptake with and without FdUrd pretreat-
ment, for all the xenografts tested. Pretreatment of mice consisted of i.v.
injection of 2.5 mg/kg FdUrd, 1 h before injection of 1 MBq [18F]FLT also
i.v. The mice were euthanized 1, 2, or 3 h after [18F]FLT injection such as
stated and biodistribution measured after dissection as described
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after injection. At 90 min, the activity accumulated within
the tumors was higher than background by a magnitude
ranging between factors of 2.7 (Ramos) and 7.5 (WiDr).
Tumors continued to accumulate [18F]FLT during the last
20 min of dynamic PET imaging. The average activity
increase per milliliter of tumor, between 68 and 88 min after
[18F]FLT injection, ranged between 9.0% (Ramos) and
14.6% (WiDr; Table 4). In contrast, the background
measured in abdomen steadily decreased over the time of
observation in all mice. The activity in the heart, important
within a few minutes after [18F]FLT injection, decreased
rapidly to reach a level comparable with background.
Correlation of PET, MRI, and Histology
of a Breast Cancer and Ramos Lymphoma
Imaging on animal-dedicated MRI and PET was performed
at 1-day intervals in mice with MDA-MB231 breast cancer
(Fig. 6) and Ramos tumor xenografts (Fig. 7). A macro-
scopic necrotic center of the MDA-MB231 appeared on
MRI as a hyperintense structure surrounded by vital tumor.
In contrast, the Ramos tumor appeared on MRI to be
uniformly viable. The same tumors investigated by PET,
using FdUrd pretreatment, showed that the entire Ramos
tumor avidly incorporated [18F]FLT, whereas in MDA-
MB231, a central hypoactive area in PET, corresponding
to the necrotic portion in MRI, was surrounded by tumor
accumulating [18F]FLT.
At the cellular level, histology showed that the Ramos
tumor was close to 100% viable and showed a pronounced
proliferative activity, as evidenced by immunohistochemis-
try. In different sections, the mitotic index was 87±22
mitoses /10 HPF, and virtually all tumor cells were MIB-1
positive. In the ”viable” rim of MDA-MB231 tumor, 95% of
cells were viable and the mitotic index was 37±14 mitoses/
10 HPF, with a MIB-1 positivity rate of 70% to 80%. In the
second breast cancer SKBR3, the “viable” tumor contained
between 20% and 35% necrotic cells, while 58±26 mitoses/10
HPF were counted with a MIB-1 positivity rate of 90% to 95%.
Discussion
The tumor uptake of [18F]FLT has been shown in various
clinical studies to be lower than with [18F]FDG [17, 23].
Despite the urgent need for a proliferation imaging agent,
[18F]FLT PET remains confined to clinical studies in
particular situations or as complement to [18F]FDG PET.
Table 3. [18F]FLT tumor and normal tissue uptake according to various timings for FdUrd pretreatment and euthanization of animals
[18F]FLT uptake (% ID/g)
Lapse of time between [18F]FLT injection and dissection 2 h 1 h
Lapse of time between FdUrd pretreatment and [18F]FLT injection Control 1 h 10 min 1 h
MDA-MB231 tumor 2.1±0.2 15.8±2.5 16.6±2.1 15.8±3.5
Liver 0.8±0.1 1.0±0.3 0.8±0.1 2.1±0.1
Kidneys 1.1±0.2 1.3±0.2 1.2±0.1 2.6±0.1
Lung 0.1±0.1 0.7±0.1 0.8±0.1 1.8±0.1
Spleen 6.1±0.6 46.7±8.1 36.5±7.1 50.7±14.0
Heart 0.7±0.1 0.7±0.1 0.7±0.1 1.9±0.5
Muscle 0.6±0.1 1.4±1.4 0.7±0.0 1.5±0.2
Bone 5.1±1.4 8.4±2.4 9.6±1.0 12.6±3.4
Skin 0.5±0.2 0.5±0.0 0.4±0.1 1.5±0.2
Stomach 0.6±0.1 0.7±0.1 0.7±0.1 1.7±0.1
Small bowel 2.5±1.5 3.3±0.5 2.4±0.0 5.2±0.1
Large bowel 1.9±0.2 2.4±0.2 1.9±0.1 3.8±0.5
Blood 1.8±0.5 2.3±0.9 2.6±0.5 2.6±0.3
Mice with subcutaneous MDA-MB231 tumors (two tumors per animal) were not pretreated (controls) or pretreated with 2.5 mg/kg FdUrd in 0.2 mL saline i.v.
After 10 or 60 min, 1-MBq [18F]FLT was also administered i.v. The animals were euthanized and organs dissected 1 or 2 h postradiotracer injection, and
biodistribution was measured as described. Note the very similar tumor (and spleen) uptake at 1 and 2 h post-[18F]FLT injection. In contrast to tumor (and
spleen), however, activity in the other normal tissues was significantly lower at 2 h compared with 1 h due to washout, leading to higher tumor-to-normal
tissue ratios at 2 h
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Fig. 4. Biodistributions of [18F]FLT in mice engrafted with
LS174T and WiDr. Mice were not pretreated or pretreated
with FdUrd 1 h before [18F]FLT injection. Results are
expressed in percentage of injected dose per gram of tissue
(mean ± 1 SD).Column break ( ): spleen = 115.8%±116.6%
and 102.6%±57.21% ID/g in mice without and with FdUrd
pretreatment, respectively.
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Different groups have observed variable effects of [18F]
FLT or [125I]IdUrd cellular uptake after exposure to
therapeutic doses of chemotherapies such as 5-fluorouracil
(5-FU) [24, 25] and others [26, 27] in vitro and in patients.
These observations, considered as a “flare” phenomenon,
were to be taken into account when interpreting [18F]FLT
PET. In our approach, we used a single i.v. injection of a
nontherapeutic dose of FdUrd, aimed at improving tumor
uptake of [18F]FLT in order to use this procedure in
diagnostic PET. We used a dosing and timing of FdUrd
pretreatment that had been studied previously in experiments
conducted with [125I]IdUrd [21] that is incorporated into
DNA.
The endogenous thymidine pool competes with [18F]FLT
uptake into proliferating cells. FdUrd directly blocks the
endogenous thymidine synthesis without any major impact
on other nucleotide pathways. The thymidine synthesis
block enhances the salvage pathway and nucleoside trans-
porters promoting enhanced cellular uptake of exogenous
thymidine and thymidine analogs. As shown here, this
strategy is well applicable to [18F]FLT PET. Since 5-FU is
partially converted to FdUrd, this could explain the previ-
ously described enhanced uptake of [18F]FLT. Unfortunately,
the conversion rate of 5-FU into FdUrd varies greatly among
patients and adequate 5-FU dosing would be challenging.
Furthermore, adverse effects due to the cytostatic action of
5-FU on RNA synthesis would limit its clinical usefulness in
an imaging application [27].
Timing of PET after [18F]FLT injection has been variable in
the literature. We therefore studied this aspect both with
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Fig. 5. Charts of dynamic PETs showing accumulation of [18F]FLT for 90 min in FdUrd pretreated mice: a WiDr and LS174T
tumors. b MDA-MB231 and SKBR3 tumors. c Ramos lymphoma tumors. d PET images of [18F]FLT distribution in a mouse
bearing the Ramos tumors.
Table 4. Increase of the [18F]FLT trapped in tumors during the last 20 min
of dynamic PET shown in Fig. 5
Average activity
66–70 min (kBq/mL)
Average activity
86–90 min (kBq/mL)
Percentage
of increase
WiDra 3,130±33* 3,586±31* 14.6
LS174Ta 4,291±45 4,727±29 10.2
MDA-MB231b 3,702±30 4,071±54 9.9
SKBR3b 3,168±28 3,502±40 10.6
Ramos (left)c 4,841±44 5,338±25 10.3
Ramos (right)c 5,584±36 6,085±58 9.0
Ramos (head) c 4,200±39 4,654±28 10.8
aTumors corresponding to Fig. 5a
bTumors corresponding to Fig. 5b
cTumors corresponding to Fig. 5c
*Activity of the [18F]FLT as measured in the different tumors (see Fig. 5)
over 5 frames of 1 min each at 66 to 70 min and 86 to 90 min after injection
is expressed as mean ± 1 SD. The measured uptake increase in percentage
(last column) was significant for each tumor when comparing the five
frames at around 68 min postinjection with those of 88 min
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biodistribution experiments and a kinetic studywithmicroPET.
A timing experiment in lymphoma xenografts showed a very
similar tumor uptake of [18F]FLT at 1 and 3 h after injection. In
normal tissues, however, washout at 3 h was much higher than
at 1 h, leading to improved tumor-to-normal tissue ratios.
The observation of prolonged retention of [18F]FLT in
lymphoma prompted the evaluation of [18F]FLT for cell
proliferation PET at 2 h after injection, which would be a
compromise between the optimal tumor-to-normal tissue
ratio observed at 3 h and the short physical half-live of F-18
of 110 min. Dynamic microPET imaging confirmed that
tumor uptake increased up to 1.5 h after [18F]FLT injection
in FdUrd pretreated mice. These results suggest that PET
performed as early as 1 h after injection would not take
optimal advantage of delayed uptake in the tumor cells and
tracer elimination from normal tissues.
The results shown here with a low-dose FdUrd pretreat-
ment of animals at 2.5 mg/kg may be clinically relevant as a
diagnostic procedure. Indeed, in early patient treatment
protocols, a bolus of FdUrd was injected daily i.v. at
30 mg/kg over the first 7 days, followed by further
administrations of 15 mg/kg over several additional days
[18]. Similarly, high doses of FdUrd have been used more
recently for therapy with bolus injections of 3 g daily
(∼50 mg/kg) into the peritoneal cavity of patients with
peritoneal tumor dissemination [28]. The difference between
bolus injection and 24-h perfusion of FdUrd was studied by
Sullivan et al. [29]. As compared with massive bolus
treatments in patients, administration of a single dose of
2.5 mg/kg used here in mice is underdosed by a factor of 10
or more. Furthermore, in previous studies, we have also
shown that a similar efficacy of FdUrd in mice was reached
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Fig. 6. MRI and PET of a MDA-MB231 tumor with a large central necrosis. T2-weighted images (a, c) obtained with MRI
scanner. PET images (b, d) of the same animal were done 120 min after injection of [18F]FLT after FdUrd pretreatment. Note that
the portion of tumor that incorporated the [18F]FLT corresponded to the viable tumor imaged by MRI. The star ( ) shows the
necrotic region of the tumor. A representative histological specimen of MDA-MB231 tumor was stained with HE (e) and MIB-1
(f). e, f: ×40 enlargement.
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with injections of between 1 and 3 mg/kg [21]. For a first
clinical trial, we therefore propose the dose of 1 mg/kg
FdUrd, corresponding to a 30- to 50-fold lower dose than
reported in daily treatment protocols using bolus injections.
While flow cytometry data from tumors grown in vivo
suggested that FdUrd had a limited time of efficacy, in the
range of about 6 h, this was also confirmed with incorpo-
ration studies with [125I]IdUrd. Finally, an innocuity test was
performed in 10 mice given a single i.v. bolus injection of
100 mg/kg FdUrd. No adverse effect was observed in terms
of body weight evolution over 2 months, leukocyte counts at
10 days after injection, nor organ appearance at macroscopic
inspection at 60 days (results not shown). Based on these
observations, we estimate that the clinical use of FdUrd at a
dose of 1 mg/kg in a single bolus i.v. injection can be
considered as safe and warrants a first clinical trial.
The competition from the endogenous thymidine pool for
cellular uptake of exogenous [18F]FLT raises another
interesting question pertaining to [18F]FLT PET. The
endogenous thymidine pool and the efficacy of thymidine
synthesis may vary from patient to patient and may likely
fluctuate depending on the nutritional status. Such variations
could lead to variable [18F]FLT tumor uptake even in
cancers of similar proliferation activity. Hence, FdUrd could
improve the consistency of [18F]FLT tumor uptake by
uncoupling it from the endogenous thymidine pool. While
serum glucose level is well monitored in patients undergoing
[18F]FDG PET and subject to hormonal control, intracellular
thymidine concentration cannot be measured before [18F]
FLT PET. The potential of FdUrd to circumvent variations
of the endogenous thymidine pool may thus present a major
advantage for the clinical use of [18F]FLT PET.
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Fig. 7. MRI and PET of nonnecrotic Ramos tumor, obtained under the same conditions as Fig. 6. The MRI (a, c) and PET
images (b, d) of the same tumors were acquired. Note that the whole tumor, which appears to be healthy by MRI, incorporated
avidly [18F]FLT as revealed by PET. The Ramos tumor was subcutaneously grafted on the top of the head of a mouse.
Representative histological specimen of the Ramos tumor, stained with HE (e) and MIB-1 (f). e, f: ×40.
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In conclusion, our in vivo data showed a marked tumor
uptake increase of [18F]FLT in FdUrd pretreated mice that
might be highly clinically relevant and warrants confirmation
in patients. Such a study is being planned in patients with
aggressive breast cancer. The information gained from the
timing and biodistribution experiments has provided impor-
tant clues for such a clinical trial. We thus propose performing
PET imaging 2 h after [18F]FLT injection, while pretreatment
with FdUrd may be similarly efficient when administered
between 10 to 60 min before injection of [18F]FLT.
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